NCT04686825已完成1 期
A Randomized, Open-label, Single-dose, 4-way Crossover Phase 1 Study to Evaluate the Food Effect on Pharmacokinetics of DA-8010 After a Single Administration of DA-8010 2.5 mg or 5 mg in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 29
- 试验地点
- 1
- 主要终点
- Peak Plasma Concentration (Cmax)
研究概览
简要总结
This is a randomized, open-label, single-dose, 4-way crossover phase 1 study to evaluate the food effect on pharmacokinetics of DA-8010 after a single administration of DA-8010 2.5 mg or 5 mg under fasting and fed states in healthy male and female subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female volunteer 19 years to 50 years
- •Body weight in the range of 45.0 to 90.0 kg and body mass index in the range of 18 to 30kg/m2
- •The subjects personally signed and dated informed consent document after informed of all patient aspects of the study, fully understanding and determined spontaneously to participate
- •The subjects who are judged appropriate to participate this clinical trial according to the physical examination, routine laboratory examination and questionnaire
排除标准
- •Subject with serious active hepatobiliary (severe hepatic failure, etc.), renal(severe renal impairment, etc.), neurologic, immunologic, respiratory, digestive, endocrine, hematologic, cardiovascular(heart failure, Torsades de pointes, etc), urologic, psychological disease or history of such disease
- •Subject Hypersensitive to any of the IP components or other drug components(Aspirin, Antibiotics, etc.)
- •Subject with gastrointestinal disease (peptic ulcer, gastritis, gastrospasm, gastroesophageal reflux disease, Crohn's disease, etc.) or history of such disease/surgery (excluding simple appendic surgery, hernia surgery, hemorrhoid surgery)
- •Subject who have blood pressure < 90 mmHg or >150 mmHg as systolic or <60 mmHg or >100 mmHg as diastolic
- •Subject who have history of drug abuse or Positive in Urine drug screen test
- •Subject who are Positivie in Alcohol breath test on screening
- •Subject who have ETC drug or oriental medicine 2 weeks prior to IP administration or OTC drug or health functional food or vitamins 1 week prior to IP administration
- •Subject who have taken a drug that induces or inhibits the drug metabolic enzyme (e.g., barbital) within 30 days prior to IP administration
- •Subject who have participated in other clinical trials within 6 months prior to the first administration of the IP
- •Subject who have had whole blood transfusion within 2 months or the apheresis within 2 weeks prior to the first administration of the IP
- •Subject with a history of regular alcohol intake(>21 units/week , 1 unit = 10 g of pure alcohol) or who are unable to quit alcohol from 3 days prior to the first administration of the IP until out of hospital
- •Smoker(excluding who quit smoking 3 months before this clinical trial) or subject who are unable to quit smoking from 3 days prior to first administration of the IP until out of hospital
- •Subject who are unable to quit food containing grapefruit from 3 days before first administration of the IP until out of hospital
- •Subject who regularly intake caffeine(> 5 units/day) or who are unable to quit caffeine/food containing caffeine from 3 days before first administration of the IP until out of hospital
- •Subject with unusual eating habits (continuous vegetarian diet, etc.) or who are unable to consume the entire diet provided in this clinical trial
- •Subject who are positive in pregnancy test or pregnant or Lactating women
- •Subject who do not agree to exclude the possibility of pregnancy using the contraception from the date of the first administration of the IP until the 4 weeks after the last administration.
研究组 & 干预措施
T3
Experimental
DA-8010 5 mg (Fasting)
干预措施: DA-8010 5mg (Fasting) (Drug)
T4
Experimental
DA-8010 5 mg (Fed)
干预措施: DA-8010 5mg (Fed) (Drug)
T1
Experimental
DA-8010 2.5 mg (Fasting)
干预措施: DA-8010 2.5mg (Fasting) (Drug)
T2
Experimental
DA-8010 2.5 mg (Fed)
干预措施: DA-8010 2.5mg (Fed) (Drug)
结局指标
主要结局
Peak Plasma Concentration (Cmax)
时间窗: 0~48hours
PK parameter
Area under the plasma concentration versus time curve (AUClast)
时间窗: 0~48hours
PK parameter
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult ParticipantsHealthy VolunteersNCT04472832Agios Pharmaceuticals, Inc.32
已完成
1 期
Effect of Food on Bioavailability of a Modified Release Formulation of ImatinibHealthyNCT00422825Novartis Pharmaceuticals16
尚未招募
1 期
To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy VolunteersType 2 Diabetes MellitusNCT06492655Chong Kun Dang Pharmaceutical28
已完成
1 期
A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379Type 2 Diabetes MellitusNCT06204107Chong Kun Dang Pharmaceutical28
已完成
1 期
Clinical Study to Evaluate the Food Effect of CKD-383 0.5/25/1000mg in Healthy VolunteersType 2 Diabetes Mellitus (T2DM)NCT06695598Chong Kun Dang Pharmaceutical30